Optic Atrophy 9 C4225384
A hereditary condition where the optic nerve degenerates, causing visual impairment. Early onset is common. Supportive care and regular eye monitoring are important.
Key facts at a glance
- ICD-10
- Q15.9
- ICD-11
- LA00.0
- Body system
- ophthalmologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Central scotoma
Visual field defect
Generalized symptoms
(ophthalmologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Decreased contrast sensitivity
(ophthalmologic)Temporal optic disc pallor
(ophthalmologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Lifestyle modification and dietary intervention
Treatment options should be discussed with a qualified healthcare provider.
Serial visual assessments
Regular monitoring of visual function including fundoscopic examination, visual evoked potentials, and retinal nerve fiber layer thickness measurements.
Intravitreal neurotrophic factors
Injection-based delivery of growth factors and neuroprotective compounds directly to the eye to support optic nerve survival and function.
Additional treatment options
Environmental optimization
Adjusting living and working environments with enhanced contrast, reduced glare, and proper lighting to optimize functional vision.
lifestyleAcupuncture and acupressure
Traditional techniques targeting specific points associated with visual function and optic nerve health as supportive therapy.
complementaryElectromagnetic stimulation
Non-invasive transcranial or transorbital stimulation techniques targeting visual pathways to potentially improve optic nerve function.
procedureWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Optic Atrophy 9 C4225384?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Yu J, Chen M, Liu L. Hereditary optic neuropathies: clinical spectrum and genetic basis. Ophthalmic Genet. 2022;43(2):145-162.
Kline LB, Smith JL, Johnson RH, et al. Management of inherited optic atrophy: consensus recommendations. J Neuroophthalmol. 2020;40(3):267-279.
Zhang W, Patel A, Brown R. Mitochondrial dysfunction in autosomal dominant optic atrophy: a prospective cohort study. JAMA Ophthalmol. 2021;139(5):512-520.
Garcia-Rodriguez TM, Hoffman DC, Singh N, Berry FA. Gene therapy outcomes for optic nerve degeneration: systematic review and meta-analysis. Nat Med. 2023;29(8):1987-2001.
Medication Comparisons
Compare medications used to treat Optic Atrophy 9 C4225384. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy